Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting

Rhea-AI Summary

Tonix Pharmaceuticals (Nasdaq: TNXP) will present a poster on Tonmya™ (cyclobenzaprine HCl sublingual tablets) at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting, March 5–8, 2026 in Salt Lake City.

Poster #50, titled "Treatment with TNX-102 SL Produces Clinically Meaningful Improvements in Patient-Centered Outcomes in Fibromyalgia," will be presented March 6, 2026 at 4:55 PM ET by Errol Gould, PhD. A copy of the presentation will be available on the company presentations webpage.

Key Figures

Conference dates: March 5–8, 2026 Poster number: #50 Poster time: March 6, 2026 at 4:55 PM ET +2 more

5 metrics

Conference dates March 5–8, 2026 AAPM PainConnect Annual Meeting schedule

Poster number #50 Tonmya fibromyalgia outcomes poster identifier

Poster time March 6, 2026 at 4:55 PM ET Scheduled presentation time for Tonmya poster

TONMYA dose 2.8 mg Cyclobenzaprine HCl sublingual tablet strength for fibromyalgia

Phase 2 trials Phase 2 TONMYA development in major depressive and acute stress disorders

Market Reality Check

Price: $13.94 Vol: Volume 378,010 is 1.14x t...

normal vol

$13.94 Last Close

Volume Volume 378,010 is 1.14x the 20-day average of 331,948, indicating slightly elevated trading interest ahead of the poster presentation. normal

Technical Shares at 13.94 trade below the 200-day MA of 26.46 and are 80.08% below the 52-week high of 69.97, but 106.21% above the 52-week low of 6.76.

Peers on Argus

TNXP is nearly flat (0.07%), while momentum data shows only one peer (NGNE) movi...

1 Down

TNXP is nearly flat (0.07%), while momentum data shows only one peer (NGNE) moving, down 2.96%. Other high-affinity peers (ANNX, CADL, OMER, VNDA) show mixed, stock-specific moves, suggesting today’s action is not part of a broad sector rotation.

Historical Context

5 past events · Latest: Feb 25 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 25	Investor conferences	Positive	+3.9%	Management highlighting TONMYA and CNS/immunology pipeline at March conferences.
Jan 30	Phase 3 data	Positive	-5.4%	Positive RESILIENT Phase 3 fibromyalgia results with significant pain and symptom improvements.
Jan 06	Investor conferences	Positive	+0.9%	CEO presentations outlining marketed products and diversified CNS and immunology pipeline.
Dec 29	Equity offering	Negative	+0.1%	$20M registered direct offering to fund commercialization and pipeline development.
Dec 29	Program update	Positive	+0.1%	Program updates for TNX-4800 Lyme prophylaxis and plans for Phase 2/3 studies.

Pattern Detected

Recent news has often led to modest moves, with mixed alignment between positive catalysts and price, including occasional selloffs on favorable clinical data.

Recent Company History

Over the last several months, Tonix has highlighted its CNS and immunology pipeline, investor conference participation, and key clinical milestones. Notably, positive Phase 3 RESILIENT data on January 30, 2026 for TONMYA in fibromyalgia coincided with a -5.38% move, while general corporate and conference updates on January 6, 2026 and February 25, 2026 saw modest gains. A $20.0 million registered direct offering on December 29, 2025 had little immediate impact. Today’s poster announcement fits into this ongoing effort to showcase TONMYA’s data and commercial story.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-09-04

The company has an active S-3/A shelf registration dated 2025-09-04, expiring on 2028-09-04. It has been used at least once (recent 424B5 on 2025-11-21). The filing is not yet effective, and no aggregate capacity details are provided here.

Market Pulse Summary

This announcement highlights further scientific visibility for TONMYA, with a fibromyalgia outcomes ...

Analysis

This announcement highlights further scientific visibility for TONMYA, with a fibromyalgia outcomes poster at AAPM and reiterated focus on CNS and immunology programs. Recent history includes a Nasdaq uplisting, positive Phase 3 data, and an active S-3/A shelf used at least once for funding. Investors may watch for how additional clinical readouts, commercialization progress, and future capital raises interact with this expanding data and conference presence.

Key Terms

sublingual, fibromyalgia, phase 2, monoclonal antibody, +3 more

7 terms

sublingual medical

"cyclobenzaprine HCl sublingual tablets), which was investigated as TNX-102 SL"

Sublingual describes a way to take a drug or supplement by placing it under the tongue so active ingredients are absorbed through the thin tissue there directly into the bloodstream. Like taking a shortcut compared with swallowing a pill, this can produce faster effects, simpler dosing and sometimes more predictable delivery. Investors watch for sublingual formulations because they can affect a product’s market appeal, regulatory pathway, pricing and competitive positioning.

fibromyalgia medical

"Improvements in Patient-Centered Outcomes in FibromyalgiaPoster #: 50Date: March 6"

Fibromyalgia is a long-term condition that causes widespread body pain, extreme tiredness, and problems with sleep, memory and mood; people often feel unusually sensitive to normal touch or pressure, and symptoms can fluctuate from day to day. It matters to investors because it affects workforce productivity, healthcare spending, and demand for treatments—so advances in diagnostics, drugs, or care delivery can change market size and company prospects, much like a fuel problem that reduces a car’s performance and reliability.

phase 2 medical

"TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

monoclonal antibody medical

"immunology programs, including monoclonal antibody TNX-4800 for Lyme disease"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

cd40 ligand inhibitor medical

"TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney"

A CD40 ligand inhibitor is a drug that blocks the CD40 ligand, a protein used by immune cells to send activation and inflammatory signals; think of it as turning down an alarm bell that rallies the immune system. Investors care because these drugs aim to treat autoimmune diseases, transplant rejection or inflammatory conditions, so their clinical trial results, safety profile and regulatory approval prospects directly affect a company’s future revenue potential and development risk.

investigational new drugs regulatory

"product development candidates are investigational new drugs or biologics; their"

Investigational new drugs are medicines that are being tested in people but have not yet been approved for general use by health authorities. They matter to investors because clinical trial results and regulatory decisions determine whether these prototypes become sellable products—success can unlock large future revenues, while failures or delays can sharply reduce a company’s expected value, much like a prototype that may or may not make it to market.

biologics medical

"product development candidates are investigational new drugs or biologics; their"

Biologics are medicines made from living cells or their components rather than from simple chemical recipes, more like a handcrafted product than a mass-produced pill. They matter to investors because they often command higher prices and longer patent protection but also carry greater manufacturing, regulatory and supply risks—so a successful biologic can boost a company’s revenue significantly, while setbacks can quickly affect its stock.

AI-generated analysis. Not financial advice.

CHATHAM, N.J., March 03, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated, commercial biotechnology company, announced today that a poster on Tonmya™ (cyclobenzaprine HCl sublingual tablets), which was investigated as TNX-102 SL, will be presented at the 2026 American Academy of Pain Medicine (AAPM) PainConnect Annual Meeting, being held March 5–8, 2026, in Salt Lake City, Utah.

A copy of the Company’s presentation will be available under the Presentations tab of the Tonix website at https://ir.tonixpharma.com/presentations.

Poster Presentation Details
Title: Treatment with TNX-102 SL Produces Clinically Meaningful Improvements in Patient-Centered Outcomes in Fibromyalgia
Poster #: 50
Date: March 6, 2026 at 4:55 PM ET
Conference: 2026 AAPM PainConnect Annual Meeting
Location: Salt Lake City, Utah
Presenter: Errol Gould, PhD, Vice President, Medical Affairs of Tonix Pharma

Tonix Pharmaceuticals Holding Corp.*
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA^TM (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company’s recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® SymTouch® and Tosymra®. Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 including those relating to the completion of the offering, the satisfaction of customary closing conditions, the intended use of proceeds from the offering and other statements that are predictive in nature. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially as a result of a number of factors, including the ability of the Company to satisfy the conditions to the closing of the offering and the timing thereof, as well as those described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the SEC on March 18, 2025, and periodic reports filed with the SEC on or after the date thereof. Tonix does not undertake an obligation to update or revise any forward-looking statement. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contacts
Jessica Morris
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 799-8599

Brian Korb
astr partners
(917) 653-5122
brian.korb@astrpartners.com

Media Contacts
Ray Jordan
Putnam Insights
ray@putnaminsights.com

FAQ

What will Tonix (TNXP) present about Tonmya at the AAPM PainConnect meeting on March 6, 2026?

Tonix will present a poster on Tonmya showing patient-centered improvements in fibromyalgia outcomes. According to the company, Poster #50 titled "Treatment with TNX-102 SL Produces Clinically Meaningful Improvements in Patient-Centered Outcomes in Fibromyalgia" is scheduled for March 6, 2026 at 4:55 PM ET.

When and where is Tonix's (TNXP) poster presentation on Tonmya scheduled at the 2026 AAPM conference?

The poster is scheduled for March 6, 2026 at 4:55 PM ET in Salt Lake City, Utah. According to the company, the presentation is Poster #50 during the 2026 AAPM PainConnect Annual Meeting held March 5–8, 2026.

Who is presenting Tonix's (TNXP) Tonmya poster at the 2026 AAPM PainConnect Annual Meeting?

Errol Gould, PhD, Vice President, Medical Affairs, will present the Tonmya poster on March 6, 2026 at 4:55 PM ET. According to the company, Dr. Gould is listed as the presenter for Poster #50 at the conference.

Will Tonix (TNXP) make the Tonmya poster available online after the AAPM 2026 presentation?

Yes, a copy of the presentation will be posted online under the company's Presentations tab. According to the company, investors can access the poster on the Tonix presentations webpage after the conference.

What is the focus of Tonix's (TNXP) poster titled about TNX-102 SL at the March 2026 AAPM meeting?

The poster focuses on clinically meaningful, patient-centered outcome improvements in fibromyalgia from TNX-102 SL (Tonmya). According to the company, the research emphasizes patient-centered outcome measures and their improvement with TNX-102 SL.